Estimating individual treatment effect on disability progression in multiple sclerosis using deep learning

Disability progression in multiple sclerosis remains resistant to treatment. The absence of a suitable biomarker to allow for phase 2 clinical trials presents a high barrier for drug development. We propose to enable short proof-of-concept trials by increasing statistical power using a deep-learning...

Descripción completa

Detalles Bibliográficos
Autores principales: Falet, Jean-Pierre R., Durso-Finley, Joshua, Nichyporuk, Brennan, Schroeter, Julien, Bovis, Francesca, Sormani, Maria-Pia, Precup, Doina, Arbel, Tal, Arnold, Douglas Lorne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9512913/
https://www.ncbi.nlm.nih.gov/pubmed/36163349
http://dx.doi.org/10.1038/s41467-022-33269-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9512913/
https://www.ncbi.nlm.nih.gov/pubmed/36163349
http://dx.doi.org/10.1038/s41467-022-33269-x

Ejemplares similares